Pathstone Holdings
PRME icon

Pathstone Holdings’s Prime Medicine PRME Stock Holding History

Pathstone Holdings’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,250
Closed -$22.4K – 2304
2025
Q1 		$22.4K Sell
11,250
-61
-0.5% -$156 ﹤0.01% 2202
2024
Q4 		$33K Sell
11,311
-3,059
-21% -$10.7K ﹤0.01% 2280
2024
Q3 		$55.6K Buy
+14,370
New +$66.6K ﹤0.01% 2277

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Pathstone Holdings's PRME Position: Q2 2025 in Review

Pathstone Holdings sold out of Prime Medicine (PRME) in Q2 2025, closing a stake of 11,250 shares — an estimated $22.4K sold.

Pathstone Holdings first reported a position in PRME in Q3 2024 and held it in 3 quarters. The position peaked at $55.6K in Q3 2024. 121 funds tracked by Wall St. Rank hold PRME as of Q2 2025.

  • Pathstone Holdings reported no remaining Prime Medicine position as of Q2 2025 after selling out during the quarter.
  • Pathstone Holdings sold 11,250 Prime Medicine shares in Q2 2025, an estimated $22.4K.
  • Pathstone Holdings first reported a position in Prime Medicine in Q3 2024 and held it in 3 quarters.
  • Pathstone Holdings's Prime Medicine position peaked at $55.6K in Q3 2024.
  • 121 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2025.

Based on Pathstone Holdings's 13F filing for Q2 2025, filed 12 Aug 2025.